I. SCOPE AND METHODOLOGY
II. REPORT SYNOPSIS
1. Introduction
Ion Channels
History
Types of Ion Channels
Voltage-Gated Ion Channel
Ligand-Gated Ion Channel
hERG Screening
About the Heart
Normal Functioning of Heart
Patch Clamp Technique
QT Interval
Short QT Syndrome
Long QT Syndrome
Types of LQTS
Genetical LQTS
Acquired LQTS
Signs and Symptoms
Drug Induced LQTS
Causes
Long QT Syndrome and Torsade de pointes
Recording the Electrical Activity of Heart Beat
Diagnosis of LQTS
Treatment
PQRST wave
Cell Lines
HEK 293 Cell Lines
CHO or Chinese Hamster Ovary Cells
2. Global Market Analysis
Exhibit 1: hERG Screening – Global Value Market Estimations & Predictions (2005 - 2015) in US$ Million (Graphical Representation Included)
Exhibit 2: List of Major Global Companies
3. Regional Market Analysis
North America
Exhibit 3: hERG Screening – North American Value Market Estimations & Predictions (2005 - 2015) in US$ Million (Graphical Representation Included)
Europe
Exhibit 4: hERG Screening – European Value Market Estimations &
Predictions (2005 - 2015) in US$ Million (Graphical Representation Included)
Asia-Pacific
Exhibit 5: hERG Screening – Asia-Pacific Value Market Estimations & Predictions (2005 - 2015) in US$ Million (Graphical Representation Included)
Rest of World
Exhibit 6: hERG Screening – Rest of World Value Market Estimations & Predictions (2005 - 2015) in US$ Million (Graphical Representation Included)
III. MARKET DYNAMICS
1. Market Overview
Global Market Analysis
Exhibit 7: hERG Screening – Global Value Market Estimations & Predictions (2005 - 2015) in US$ Million by Geographic Region for North America, Europe, Asia-Pacific, and Rest of World (Graphical Representation Included)
Exhibit 8: hERG Screening – Global Value Market Shares (2009 & 2015) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World (Graphical Representation Included)
The Impact of hERG Screening
2. Major Companies in hERG Screening Industry
Abcam plc (UK)
Abnova Corporation (Taiwan)
Astra Zeneca International (UK)
Aureus Sciences (France)
Aurora Biomed, Inc. (Canada)
More…
3. Major Activities in hERG Screening Industry
MDS Inc. Renamed Nordion Inc.
Merck KGaA, Darmstadt Acquires Millipore and Forms New EMD Millipore Division
AGTC Acquires Technology from Icagen
Essen BioScience and Nycomed in Ion Channel Drug Discovery Collaboration
Essen Instruments and Origene Technologies to Develop Ion Channel Cell Lines in Collaboration
Ricerca Biosciences LLC Buys MDS Pharma Services
Sophion Launches New, Simplified Version, Lower Throughput QPatch 8
Fluxion Biosciences Launches Fully Automated IonFlux Ion Channel Screening Platform
Cellectricon and Bio Focus DPI advance high throughput ion channel drug discovery
Icagen Initiates Study of Senicapoc in Exercise Induced Asthma
More….
4. Regional Market Analysis
A. North America
Market Analysis
Exhibit 9: hERG Screening – North American Value Market Estimations & Predictions (2005 - 2015) in US$ Million (Graphical Representation Included)
Exhibit 10: List of Major Companies in North America
Analysis by Country
Exhibit 11: hERG Screening – North American Value Market Estimations & Predictions (2005 - 2015) in US$ Million by Country for United States and Canada (Graphical Representation Included)
Exhibit 12: hERG Screening – North American Value Market Shares (2009 & 2015) by Country for United States and Canada (Graphical Representation Included)
B. Europe
Market Analysis
Exhibit 13: hERG Screening – European Value Market Estimations & Predictions (2005 - 2015) in US$ Million (Graphical Representation Included)
Exhibit 14: List of Major Companies in Europe
Analysis by Country
Exhibit 15: hERG Screening – European Value Market Estimations & Predictions (2005 - 2015) in US$ Million by Country for United Kingdom, Germany, France, Switzerland, and Rest of Europe in US$ Million (Graphical Representation Included)
Exhibit 16: hERG Screening – European Value Market Shares (2009 & 2015) by Country for United Kingdom, Germany, France, Switzerland and Rest of Europe (Graphical Representation Included)
C. Asia-Pacific
Market Analysis
Exhibit 17: hERG Screening – Asia-Pacific Value Market Estimations & Predictions (2005 - 2015) in US$ Million (Graphical Representation Included)
Exhibit 18: List of Major Companies in Asia-Pacific
Analysis by Country
Exhibit 19: hERG Screening – Asia-Pacific Value Market Estimations & Predictions (2005 - 2015) in US$ Million by Country for Australia, China, India, and Rest of Asia-Pacific in US$ Million (Graphical Representation Included)
Exhibit 20: hERG Screening – Asia-Pacific Value Market Shares (2009 & 2015) by Country for Australia, China, India and Rest of Asia-Pacific (Graphical Representation Included)
D. Rest of World
Market Analysis
Exhibit 21: hERG Screening – Rest of World Value Market Estimations & Predictions (2005 - 2015) in US$ Million (Graphical Representation Included)
5. Technology Comparison
Patch Clamp Technology
Exhibit 22: Patch Clamp Technology - Estimated Market Value by Company in US$ Million for 2010
Exhibit 23: Patch Clamp Technology - Estimated Value Market Shares by Company for 2010
hERG Screening Assays
Exhibit 24: hERG Screening Assays - Estimated Market Value by Company in US$ Million for 2010
Exhibit 25: hERG Screening Assays - Estimated Market Shares by Company for 2010
hERG Screening Antibodies & Cell Lines
Exhibit 26: hERG Screening Antibodies and Cell Lines - Estimated Market Value by Company in
US$ Million for 2010
Exhibit 27: hERG Screening Antibodies and Cell Lines - Estimated Market Shares
by Company for 2010
IV. PRODUCT/TECHNOLOGY RESEARCH
1. Introduction
Channelopathies
Ion Channel Safety Pharmacology
Ion Channels as Pharmaceutical Targets
What makes Ion channels attractive targets for drug development
Patch-clamp: the gold standard
Ion Channel
Basic Features of Ion Channel
Biological Role
Diseases Related to Ion Channels
Exhibit 28: Diseases Related to Ion Channel Function.
Ion Channel Genes of the Human Genome
Technologies for Ion Channel Characterization
Towards Ion Channel Drug Discovery and Development
Physiological Significance of Ion Channels
Flux Assays in Ion Channel Screening
Types of Ion Channels
Voltage-gated Ion Channel
Structure
Exhibit 29: List of Known Human Voltage-Gated Potassium Channel Alpha Subunits
Exhibit 30: List of Voltage-Gated Potassium Channel Beta Subunits
Mechanism
Ligand-gated Ion Channel
Introduction
Regulation
Clinical Relevance
hERG
Role of hERG Blockers in Cardiac Disorders
Characteristics and Clinical Applications of Cardiac hERG/I (Kr) Potassium Channel
Biophysical Properties and Molecular Determinants of ziprasidone and its Role in
Block Opening hERG
Cell Lines
HEK 293 Cell Lines:
History
Exhibit 31: Companies Developing Cell lines for hERG Screening
Application of HEK 293 Cells
CHO or Chinese Hamster Ovary Cells
hERG T-REx™ CHO Cells
Role of Potassium, Magnesium and Calcium in Normal Functioning of Heart
Magnesium
Calcium
Potassium
Membrane Potential
Improper Membrane Potential
Description
Task in Human Well being
Common Abnormalities and Ailments
Atrial Arrhythmias
Ventricular Arrhythmias
Arrhythmias Arising Because of Abnormalities in the AV node, Purkinje fibers, or Bundle of His
Functioning of Heart
Cardiac Phase
Electrocardiogram (EKG or ECG):
History
QRS Complex:
T wave
Abnormality in Potassium Ion Channel
Torsades de Pointes : a cardiac arrhythmia
Characteristics of TdP
Causes of TdP
Risk factors for TdP
Treatment
QT Interval
Short QT Syndrome
Long QT Syndrome
LQTS – Causes
LQTS – Risks
LQTS – Signs and Symptoms
Screening and Diagnostic Procedures
Complications
LQTS - Treatment
Medical Devices and Surgical Procedures
Clinical Trials
Prevention
Self-care
Coping Skills
Lifestyle Changes
LQTS – The Types
Inherited Long QT syndrome
Exhibit 32: Drugs to be Avoided by Congenital QT Patients
Exhibit 33: Drugs (Withdrawn From Market) Avoided by Congenital QT Patients
Genetic Basis of LQTS
LQTS Associated Syndromes
Precautions
Acquired Long QT Syndrome
Exhibit 34: Drugs Which Block the hERG Channel.
Co-factors of Drug Induced LQTS
Symptoms for Identification of Drug Induced LQTS
High probability of Drug Induced LQTS
Suspected Cases of Drug Induced LQTS
Unlikely Case of Drug Induced LQTS
Patch Clamp Technique
Methodology
Technique Configurations
On-cell
Inside out
Whole-cell
Outside out
Perforated whole-cell
The Patch Clamp Technique Application
QPatch 16
QPatch HT
Exhibit 35: List of Companies Developing Patch clamp
Q Patch Applications
QPATCH HT: Effective Application in Ion Channel Drug Discovery
Screening Station
Plates
The Q Plate Technique
Q Plate Prospects
Cell Preparation Unit
Liquid Handling System
Touch Screen
Data Acquisition
Q Patch software
Exhibit 36: Companies Developing hERG Soft Ware.
hERG Screening in Drug Discovery
Action from Drug Approving Authorities
Exhibit 37: Drugs (Discontinued in the Market) which Block the hERG Channel.
In silico Modeling in hERG Channel Blockers
hERG Channel Archetypes and Pharmacophores
Testing In Silico for hERG K+ Channel Blockers
In Silico Categorization of hERG Channel Blockers: a Skill-Based Strategy
hERG Screening – Drugs Banned
Exhibit 38: List of Banned Drugs for Inducing LQTS
hERG and Obesity
2. Product Trends
The GLP hERG Channel Assay
Benefits Attributed to the Use of CDI Services
ICR 8000 – The latest Entrant in the Ion Channel Technology
Applications of ICR 800
Features and Parameters of ICR 800
Uses
ICR 12000
Features and Parameters of ICR 12000
Exhibit 39: Companies Offering hERG Screening Services
Rubidium Flux Assay
IonWorks® HT in hERG Channel Screening
Measurement of hERG Channel Currents Using IonWorks HT System
Sophion’s Q Patch
QPatch 16
QPatch HT
Cell Lines in hERG Screening
Exhibit 40: List of hERG Screening Products/Technologies/Services by Company
3. Research Briefs
NMR Solution Structure of N-Terminal Domain of hERG
Fluconazole Inhibits hERG K+ Channel Directly Blocking and Disrupting Protein Trafficking
Prediction of the hERG Potassium Channel Inhibition Potential with use of Artificial Neural Networks
Analysis of hERG Current Assay Performance: From Preclinical Safety Studies to Clinical QT Prolongation
Characterization of Recombinant hERG K+ Channel Inhibition by the Active Metabolite of Amiodarone Desethyl-Amiodarone
Trafficking-Competent KCNQ1 Variably Influences the Function of hERG Long QT Alleles
Protocol-Dependence of hERG K channel inhibition at 37° C: Cisapride v/s Dofetilide
Block Effects of Capsaicin on hERG Potassium Currents is Improved by S6 Mutation at Y652
Role of Hsp 90 and ROS in Blocking Maturation and Trafficking of hERG K + Channel Protein during Hypoxia
Measurement of hERG Current IC50 using PatchXpress
Electrophysiologic Characterization of a Novel hERG Channel Activator
Effects of Sophocarpine and Sophoridine on hERG K+ channel – Comparison
Concentrations of the Test Article in the hERG Assay: Differences in Solubility, Stability and Perfusion
Description About “hot spot” Refers to hERG Blockade Activity to a-Scorpion Toxins Affecting K+ Channels
FRET with Several Labeled hERG K+ Channels as a Reporter in In Vivo Coarse Architecture of the Cytoplasmic Domains
Recurrent Intrauterine Fetal Loss by the Absence of hERG: Clinical and Functional Characterization of a Homozygous Nonsense hERG Q1070X Mutation
Silencing of hERG Gene by shRNA Inhibits SH-SY5Y Cell Growth In Vitro and In Vivo
Exploring QSTR and Toxicophore of hERG K+ Channel Blockers Using GFA and HypoGen Techniques
Analogs of MK-499 are Differentially Affected by a Mutation in the S6 Domain of the hERG K+ Channel
Effect of Chemical Oxidation of hERG Channels
Blockade of hERG Channel by Drugs
Antipsychotic Drug Thioridazine Block hERG K + Channel: An Obligatory Function of the S6 Helix Residue F656
hERG Gene and ATP-Sensitive Potassium Channels are the Targets for Adverse Drug Effects
Ketoconazole Inhibits hERG K+ Channel Depending on Channel Gating
Hypothesis Conducted to Better Understand the Binding Mode of hERG Channel Blockers
In Vitro Modulation of hERG Channels by Organochlorine Solvent Trichlormethane as Potential Explanation for Proarrhythmic Effects of Chloroform
Inhibition of Cardiac hERG Potassium Channels by Antidepressant Maprotiline
Erythromycin block of the hERG K+ channel and its accessibility option to F656 and Y652
Inhibition of hERG Channel by Ziprasidone
hERG Channel Inhibition and QT Interval Prolongation - An Evaluation of Emerging Trends
hERG-Lite®: Complete High-Throughput Screening Solution for Drug-Induced hERG Risk
Estimation of Potency of hERG Channel Blockers
Lidoflazine is a High Affinity Blocker of the hERG K+Channel
Comparison of Kinetic Properties of Quinidine and Dofetilide Block of hERG Channels
hERG Binding Specificity and Binding Site Structure: Evidence from a Fragment-based Evolutionary Computing SAR Study
Zebrafish Embryos Express an Orthologue of hERG
Phenytoin and Phenobarbital Inhibit Human hERG Potassium Channels
Characterization of Recombinant hERG K+ Channel Blockade using Class Ia Antiarrhythmic Drug Procainamide
Finding Solutions to the Problems with In Vitro Screening of Drugs for QT Interval Prolongation Applying hERG K+ Channels Expressed in Mammalian Cell Lines and Xenopus Oocytes
Fenamate-Induced Enhancement of Heterologously Expressed hERG Currents in Xenopus Oocytes
hERG K Channels as Pharmacological Targets
4. hERG Screening -The Market Outlook
V. CORPORATE DIRECTORY
VI. PATENTS INFORMATION